Somatic mutation and functional polymorphism of a novel regulatory element in the HGF gene promoter causes its aberrant expression in human breast cancer

Journal of Clinical Investigation

Volumn 119, Issue 3, 2009, Pages 478-491

  Ma, Jihong ^a   DeFrances, Marie C ^a   Zou, Chunbin ^a   Johnson, Carla ^a   Ferrell, Robert ^b   Zarnegar, Reza ^a  

^a UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF PITTSBURGH GRADUATE SCHOOL OF PUBLIC HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DEOXYADENOSINE; DEOXYADENOSINE TRACT ELEMENT; DNA; MESSENGER RNA; SCATTER FACTOR; UNCLASSIFIED DRUG;

ALLELE; ARTICLE; BREAST CANCER; CANCER INCIDENCE; CHROMATIN STRUCTURE; CHROMOSOME ABERRATION; CONTROLLED STUDY; FEMALE; GENE DELETION; GENE EXPRESSION; GENE TARGETING; GENETIC MARKER; GENETIC POLYMORPHISM; GENETIC TRANSCRIPTION; HUMAN; HUMAN CELL; HUMAN TISSUE; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN DNA INTERACTION; REGULATORY MECHANISM; SOMATIC MUTATION; UTERINE CERVIX CARCINOMA; WILD TYPE;

ADULT; AFRICAN AMERICANS; AGE FACTORS; BINDING SITES; BIOLOGICAL MARKERS; BREAST NEOPLASMS; CARCINOMA; CCAAT-ENHANCER-BINDING PROTEIN-BETA; CELL LINE, TUMOR; CHROMATIN ASSEMBLY AND DISASSEMBLY; DNA; DNA-BINDING PROTEINS; EUROPEAN CONTINENTAL ANCESTRY GROUP; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; GENOTYPE; HEPATOCYTE GROWTH FACTOR; HUMANS; MAMMARY GLANDS, HUMAN; MODELS, BIOLOGICAL; POLY A; POLY(ADP-RIBOSE) POLYMERASES; POLYMORPHISM, GENETIC; PROMOTER REGIONS, GENETIC; PROTEIN BINDING; PROTO-ONCOGENE PROTEINS C-MET; RECEPTORS, GROWTH FACTOR; REGULATORY ELEMENTS, TRANSCRIPTIONAL; RISK FACTORS; RNA, SMALL INTERFERING; SEQUENCE DELETION; UTERINE CERVICAL NEOPLASMS;

EID: 67650831418     PISSN: 00219738     EISSN: 15588238     Source Type: Journal    
DOI: 10.1172/JCI36640     Document Type: Article

References (42)

1. Hanahan, D., and Weinberg, R.A. 2000. The hallmarks of cancer. Cell. 100:57-70.
2. Trusolino, L., and Comoglio, P.M. 2002. Scatter-factor and semaphorin receptors: Cell signaling for invasion growth. Nat. Rev. Cancer. 2:289-300.
3. Birchmeier, C., Birchmeier, W., Gherardi, E., and Vande Woude, G.F. 2003. Met, metastasis, motility and more. Nat. Rev. Mol. Cell Biol. 4:915-925.
4. Wang, X., et al. 2002. A mechanism of cell survival: sequestration of Fas by the HGF receptor Met. Mol. Cell. 9:411-421.
5. Zhang, Y.-W., and Vande Woude, G.F. 2003. HGF/SFmet signaling in the control of branching morphogenesis and invasion. J. Cell Biochem. 88:408-417.
6. Bell, A., Chen, Q., DeFrances, M.C., Michalopoulos, G.K., and Zarnegar, R. 1999. The five amino aciddeleted isoform of hepatocyte growth factor promotes carcinogenesis in transgenic mice. Oncogene. 18:887-895.
7. Corso, S., Comoglio, P.M., and Giordano, S. 2005. Cancer therapy: can the challenge be MET? Trends Mol. Med. 11:284-292.
8. Gallego, M.I., Bierie, B., and Hennighausen, L. 2003. Targeted expression of HGF/SF in mouse mammary epithelium leads to metastatic adenosquamous carcinomas through the activation of multiple signal transduction pathways. Oncogene. 22:8498-8508.
9. Bogenrieder, T., and Meenhard, H. 2003. Axis of evil: molecular mechanisms of cancer metastasis. Oncogene. 22:6524-6536.
10. Yamashita, J., et al. 1994. Immunoreactive hepatocyte growth factor is a strong and independent predictor of recurrence and survival in human breast cancer. Cancer Res. 54:1630-1633.
11. Toi, M., et al. 1998. Significance of circulating hepatocyte growth factor level as a prognostic indicator in primary breast cancer. Clin. Cancer Res. 4:659-664.
12. Taniguchi, T., et al. 1995. Serum concentrations of hepatocyte growth factor in breast cancer patients. Clin. Cancer Res. 1:1031-1034.
13. Kang, J.Y., et al. 2003. Tissue microarray analysis of hepatocyte growth factor/Met pathway components reveals a role for Met, matriptase, and hepatocyte growth factor activator inhibitor 1 in the progression of node-negative breast cancer. Cancer Res. 63:1101-1105.
14. Parr, C., Watkins, G., Mansel, R.E., and Jiang, W.G. 2004. The hepatocyte growth factor regulatory factors in human breast cancer. Clin. Cancer Res. 10:202-211.
15. Tuck, A.B., Park, M., Sterns, E.E., Boag, A., and Elliott, B.E. 1996. Coexpression of hepatocyte growth factor and receptor (Met) in human breast carcinoma. Am. J. Pathol. 148:225-232.
16. Jiang, J.G., Johnson, C., and Zarnegar, R. 2001. Peroxisome proliferator-activated receptor gammamediated transcriptional up-regulation of the hepatocyte growth factor gene promoter via a novel composite cis-acting element. J. Biol. Chem. 276:25049-25056.
17. Jiang, J.G., Bell, A., Liu, Y., and Zarnegar, R. 1997. Transcriptional regulation of the hepatocyte growth factor gene by the nuclear receptors chicken ovalbumin upstream promoter transcription factor and estrogen receptor. J. Biol. Chem. 272:3928-3934.
18. Seol, D.-W., Chen, Q., and Zarnegar, R. 2000. Transcriptional activation of the Hepatocyte Growth Factor receptor (c-met) gene by its ligand (Hepatocyte Growth Factor) is mediated through AP-1. Oncogene. 19:1132-1137.
19. Jiang, J.G., and Zarnegar, R. 1997. A novel transcriptional regulatory region within the core promoter of the hepatocyte growth factor gene is responsible for its inducibility by cytokines via the C/EBP family of transcription factors. Mol. Cell. Biol. 17:5758-5770.
20. Bell, A.W., Jiang, J.G., Chen, Q., Liu, Y., and Zarnegar, R. 1998. The upstream regulatory regions of the hepatocyte growth factor gene promoter are essential for its expression in transgenic mice. J. Biol. Chem. 273:6900-6908.
21. Elliott, B.E., Hung, W.L., Boag, A.H., and Tuck, A.B. 2002. The role of hepatocyte growth factor (scatter factor) in epithelial-mesenchymal transition and breast cancer. Can. J. Physiol. Pharmacol. 80:91-102.
22. Wojcik, E.J., et al. 2006. A novel activating function of c-Src and Stat3 on HGF transcription in mammary carcinoma cells. Oncogene. 25:2773-2784.
23. Price, M., Fivaz, J., Jotteran, A., and Mirkovitch, J. 1998. Tissue-specific chromatin structure at the hepatocyte growth factor/scatter factor gene promoter. Gene. 211:141-150.
24. Zou, C., et al. 2007. Lack of Fas antagonism by Met in human fatty liver disease. Nat. Med. 13:1078-1085.
25. Shimizu, M., Mori, T., Sakurai, T., and Shindo, H. 2000. Destabilization of nucleosomes by an unusual DNA conformation adopted by poly(dA) ·poly(dT) tracts in vivo. EMBO J. 19:3358-3365.
26. Koch, K.A., and Thiele, D.J. 1999. Functional analysis of a homopolymeric (dA-dT) element that provides nucleosomal access to yeast and mammalian transcription factors. J. Biol. Chem. 274:23752-23760.
27. Fox, K.R. 1992. Wrapping of genomic poly dA.poly dT tracts around nucleosome core particles. Nucleic Acid Res. 20:1235-1242.
28. Iyer, V., and Struhl, K. 1995. Poly (dA:dT), a ubiquitous promoter element that stimulates transcription via its intrinsic DNA structure. EMBO J. 14:2570-2579.
29. Anderson, J.D., and Widom, J. 2001. Poly(dA-dT) promoter elements increase the equilibrium accessibility of nucleosomal DNA targets. Mol. Cell. Biol. 21:3830-3839.
30. Reardon, B.J., Winters, R.S., Gordon, D., and Winters, E. 1993. A peptide motif that recongnizes AT tracts in DNA. Proc. Natl. Acad. Sci. U. S. A. 90:11327-11331.
31. Zahnow, C., Younes, P., Laucirica, R., and Rosen, J.M. 1997. Overexpression of C/EBPβ-LIP, a naturally occurring dominant negative transcription factor in human breast cancer. J. Natl. Cancer Inst. 89:1887-1891.
32. Yokota, T., et al. 2007. Differential regulation of elafin in normal and tumor-derived mammary epithelial cells is mediated by CCAAT/enhancer binding protein beta. Cancer Res. 67:11272-11283.
33. Cervellera, M.N., and Sala, A. 2000. Poly (ADPribose) polymerase is a B-MYB coactivator. J. Biol. Chem. 275:10692-10696.
34. Kraus, W.L., and Lis, J.T. 2003. PARP goes transcription. Cell. 113:677-683.
35. Elser, M., et al. 2008. Poly(ADP-ribose) polymerase 1 promotes tumor cell survival by coactivating hypoxia-inducible factor-1-dependent gene expression. Mol. Cancer Res. 6:282-290.
36. Loeb, L.A. 2001. A mutator phenotype in cancer. Cancer Res. 61:3230-3239.
37. Kim, K.M., et al.2002. PolyA deletions in hereditary nonpolyposis colorectal cancer: mutations before a gatekeeper. Am. J. Pathol. 160:1503-1506.
38. Samowitz, W.S., Slattery, M.L., Potter, J.D., and Leppert, M.F. 1999. BAT-26 and BAT-40 instability in colorectal adenomas and carcinomas and germline polymorphisms. Am. J. Pathol. 154:1637-1641.
39. Wild, P.J., et al. 2004. Microsatellite instability predicts poor short-term survival in patients with advanced breast cancer after high-dose chemotherapy and autologous stem-cell transplantation. Clin. Cancer Res. 10:556-564.
40. Soler-Vila, H., Kasl, S.V., and Jones, B.A. 2003. Prognostic significance of psychosocial factors in African-American and white breast cancer patients: a population-based study. Cancer. 98:1299-1308.
41. Ademuyiwa, F.O., and Olopade, O.I. 2003. Racial differences in genetic factors associated with breast cancer. Cancer Metastasis Rev. 22:47-53.
42. Bacon, A.L., Dunlop, M.G., and Farrington, S.M. 2001. Hypermutability at a poly (A/T) tract in the human germline. Nucleic Acids Res. 29:4405-4413.